Summary: Maraviroc is the first CCR5 coreceptor antagonist to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of CCR5-tropic human immunodeficiency virus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback